Skip to main content

NICE TAs

05/11/2025
TA1107: Delgocitinib for treating moderate to severe chronic hand eczema
05/11/2025
TA1106: Cabotegravir for preventing HIV-1 in adults and young people
05/11/2025
TA1108: Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
22/10/2025
TA1105: Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)
22/10/2025
TA1104: Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)
21/10/2025
TA1103: Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
08/10/2025
TA1101: Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over
01/10/2025
TA1099: Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy
24/09/2025
TA1098: Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable
11/09/2025
TA1097: Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable
28/08/2025
TA1093: Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over
28/08/2025
TA1095: Guselkumab for previously treated moderately to severely active Crohn's disease
28/08/2025
TA1094: Guselkumab for treating moderately to severely active ulcerative colitis
27/08/2025
TA1092: Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
26/08/2025
TA1028: Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)
20/08/2025
TA1091: Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments
19/08/2025
TA1090: Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma
13/08/2025
TA1088: Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
06/08/2025
TA1086: Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
06/08/2025
TA1087: Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
Follow AWTTC: